HTA and pricing update: Recent moves on drug cost-control by European payers

By Chloe Sheppard, Analyst Email: csheppard@partners4access.com The issue of affordability and access to medicines has been brought to the forefront of policymakers’ and payers’ attention in Europe thanks to the COVID-19 pandemic. Summarised below are some recent changes to HTA and pricing processes and discussions from payers across Italy, Germany and Spain, which highlight how…

Driving patient access for treatments targeting rare genetic disorders in the Middle East

By Ciaran Cassidy, S Analyst Email: ccassidy@partners4access.com At the World Orphan Drug Conference (WODC) this year Dr Maryam Matar presented on the success of the UAE genetic disease association (UAEGDA), an organisation which she founded in 2006 and currently chairs. The UAEGDA is a non-governmental organisation focused on controlling genetic disorders prevalent in the United…

Under the microscope: Orphan Drug incentives in Europe

By Chloe Sheppard, Analyst Email: csheppard@partners4access.com The European Commission is imminently expected to publish a report evaluating the pros and cons of the EU Orphan and Paediatric Legislation introduced 20 years ago. The regulation has so far had success towards its primary goal to incentivise the development of orphan medicinal products (OMPs) for patients living…

France to place restrictions on Nominative ATU

By Erfan Akbarain, Analyst Email: eakbarain@partners4access.com France’s National Agency for the Safety of Medicines and Health Products (ANSM)1 governs the early access program called autorisation temporaire d’utilisation (ATU). The ANSM are expected to implement changes set by the French social security law to the nominative ATU program later this year to ease the cost burden…

Cancelled meetings and assessment delays: HTA bodies are revising priorities in response to COVID-19

By Nicola Allen, Associate Director Email: nallen@partners4access.com The priorities of health technology assessment (HTA) bodies are evolving as health care systems around the world are seeking to manage the strain of the Covid-19 pandemic and the biopharmaceutical industry are rising to the challenge to find an effective treatment. Initially, agencies moved in-person meetings to teleconferences…

Deadline day approaches for Israel’s market entry hopefuls

By Erfan Akbraian, Analyst Email: eakbraian@partners4access.com Majority of orphan drug manufacturers do not currently view Israel as an early launch opportunity. However, universal reimbursed access to high quality healthcare which is at par with Western European countries, combined with the expansion of the prenatal and new-born screening programmes[1] that have considerably improved diagnosis rates is…